News

The Phase 1 trial is investigating the pharmacology, pharmacokinetics, safety and efficacy of NKTR-181 in around 75 healthy subjects. Nektar is expecting to conclude the study in the

The trial expects to investigate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. Previous studies showed that 63% of patients

Ventrus has submitted a new SPA that includes a revised protocol, including the newly defined endpoints, in accordance with the feedback received from that meeting, and expects a

The deal expands BD’s presence into the emerging affordable personal flow cytometer space, and also expands the use of flow cytometry technology. BD Biosciences president William Rhodes said

The screening panels allow researchers to simultaneously examine key genes that are associated with X-chromosome disorders and syndromic forms of Autism Spectrum Disorder (ASD). The RainDance ASDSeq and

The active substance of Yellox is bromfenac, an anti-inflammatory agent, non-steroids, ATC code: S01BC11, with mechanism of action through blockage of the prostaglandin synthesis by inhibiting primarily cyclooxygenase

Teva Pharma said that the positive opinion was based on the significant results from the clinical trials evaluating, NOMAC-E2. NOMAC-E2 is a monophasic regimen containing an estrogen which

Avid, a wholly-owned subsidiary of Eli Lilly. Lilly acquired Avid Radiopharmaceuticals in December 2010. Amyvid is a molecular imaging agent under investigation for Positron Emission Tomography (PET) imaging

The company has posted loss from operations of $6.2m, compared to $3.26m for the comparable period in 2009. For the full year ended 31 December 2010, the company